The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines
- 28 August 2007
- Vol. 25 (42), 7372-7378
- https://doi.org/10.1016/j.vaccine.2007.08.014
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- The Interferon Antagonist NS2 Protein of Respiratory Syncytial Virus Is an Important Virulence Determinant for HumansThe Journal of Infectious Diseases, 2006
- Pathogenesis of Respiratory Syncytial Virus Infection in the Murine ModelProceedings of the American Thoracic Society, 2005
- Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in InfantsThe Journal of Infectious Diseases, 2005
- A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus DiseaseThe Journal of Experimental Medicine, 2002
- Illness Severity, Viral Shedding, and Antibody Responses in Infants Hospitalized with Bronchiolitis Caused by Respiratory Syncytial VirusThe Journal of Infectious Diseases, 2002
- Evaluation of a Live, Cold‐Passaged, Temperature‐Sensitive, Respiratory Syncytial Virus Vaccine Candidate in InfancyThe Journal of Infectious Diseases, 2000
- The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in ChildrenNew England Journal of Medicine, 1998
- Evaluation of Two Live, Cold‐Passaged, Temperature‐Sensitive Respiratory Syncytial Virus Vaccines in Chimpanzees and in Human Adults, Infants, and ChildrenThe Journal of Infectious Diseases, 1997
- Twenty Years of Outpatient Respiratory Syncytial Virus Infection: A Framework for Vaccine Efficacy TrialsPediatrics, 1997
- A Cold-Passaged, Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L GenesVirology, 1995